Listen

The Whole New World of SGLT-2 Inhibitors: Looking into the Cardio-Kidney-Metabolic Space

This educational activity will provide an overview of CKM syndrome and evidence supporting early screening and treatment. The latest data from all landmark clinical trials, systematic reviews, and meta-analyses demonstrating the benefit of SGLT2 inhibitors on cardiorenal outcomes and clinical trials currently underway to identify potential emerging areas for SGLT2 inhibitor benefit will be presented. A review of the latest clinical practice guidelines for the use of SGLT2 inhibitors in heart failure, kidney disease, and diabetes will be shared. The activity will conclude with an exploration of interprofessional care models that address barriers and incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.

Monday, Dec. 9
11:30 a.m. - 1 p.m. CT (12:30 - 2 p.m. ET)

Symposium Location: Room 291, Level 2, Ernest N. Morial Convention Center

Come early! Seating is limited and provided on a first-come, first-served basis.

Can't make it to New Orleans? Tune into the Free Live Webinar Broadcast.
Registration is required for the webinar.

Webinar Registration

Speakers

Leo F. Buckley PharmD, MPH, BCCP, Activity Chair
Clinical Pharmacy Specialist
Brigham and Women’s Hospital
Boston, Massachusetts

Leo F. Buckley, PharmD, MPH, BCCP is a Clinical Pharmacy Specialist in the Department of Pharmacy at Brigham and Women's Hospital in Boston, Massachusetts. He graduated from Northeastern University's School of Pharmacy and completed residencies in Pharmacy Practice and Cardiovascular Pharmacotherapy at Brigham and Women's Hospital. After a research fellowship at Virginia Commonwealth University, he returned to Brigham and Women's where he leads a cardiovascular pharmacology research program and practices as a clinical pharmacist. His clinical and research interests include cardio-renal inflammation and metabolism.

Susan Cornell PharmD, CDCES, FAPhA, FADCES
Director of Experiential Education, Professor in Pharmacy Practice – Midwestern University College of Pharmacy, Downers Grove, IL
Diabetes Care & Education Specialist – Bolingbrook Christian Health Center
Bolingbrook, Illinois

Susan Cornell, PharmD, CDCES, FAPhA, FADCES is the director of experiential education and professor in the department of pharmacy practice at Midwestern University College of Pharmacy in Downers Grove, Illinois. Dr. Cornell is also a clinical pharmacist and certified diabetes care and education specialist with the Bolingbrook Christian Health Center, where she trains, educates, and supervises students from the colleges of medicine, pharmacy, and health sciences, as they provide medication therapy management and diabetes care and education for underserved populations.

Dr. Cornell served as President of the Illinois Pharmacists Association in 2011. She has received numerous awards and recognitions, including the 2024 APhA-ASP Outstanding Chapter Advisor Award, 2022 ADCES Allene Von Son Distinguished Serves Award, the 2021, 2019 and 2011 MWU Outstanding Faculty Advisor, 2017 ADCES Outstanding Illinois Diabetes Educator of the Year, and the 2014 Bowl of Hygeia, to list a few. She is an active member of the American Diabetes Association. She is also actively involved with the Association of Diabetes Care and Education Specialists, where she previously served on their board of directors and continues to assist on various committees.

Dr. Cornell has been invited to give numerous presentations to various healthcare professionals and community groups worldwide. She has served as editor, as well as, published and contributed to many peer-reviewed, professional written and online publications. Dr. Cornell is the associate editor of the ADCES Art and Science of Diabetes Care and Education Desk Reference- 3rd thru 6th edition.

Target Audience

This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, community pharmacies, and ambulatory clinics who care for or are interested in the care of patients who have type 2 diabetes, heart failure, and/or chronic kidney disease.

Learning Objectives

Identify people who have T2D, HF, and/or CKD who would benefit from early initiation of SGLT2 inhibitor therapy.
Formulate an evidence-based treatment plan to reduce cardiorenal risk in people with cardio-renal-metabolic comorbidities based on current clinical practice guidelines and person-specific factors.
Apply best practices from interprofessional care models that support the implementation of cardio-renal-metabolic therapies in different practice settings.

Agenda

11:30 a.m. – Welcome and Introductions
Leo F. Buckley
11:35 a.m. – The Heart of it All: Identifying People Who May Benefit from SGLT2 Inhibitor Treatment
Leo F. Buckley
11:50 a.m. – Filtering the Evidence: Designing Individualized SGLT2 Inhibitor Treatment Plans for People with T2D, HF, and/or CKD Based on Guidelines and Evidence-Based Practices
Susan Cornell
12:20 p.m. – Putting It into Practice (Case-based Examples): Interprofessional Care Models for the Initiation and Optimization of Therapy in People with T2D, HF, and/or CKD
All Faculty
12:50 p.m. – Faculty Discussion, Questions and Answers
All Faculty

Accredited for CPE

ACPE #: 0204-0000-24-406-L01-P
E Credit: 1.5 contact hours (0.15 CEUs)
Activity Type: Application-based
Activity Fee: No charge

To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.